Holen Sie sich die Stockscreener-App
12.98
5.96%
0.73
Vorhandelsmarkt:
13.32
0.34
+2.62%
Schlusskurs vom Vortag:
$12.25
Offen:
$12.5
24-Stunden-Volumen:
695.75K
Relative Volume:
2.67
Marktkapitalisierung:
$454.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.42%
1M Leistung:
-36.09%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.24
$13.62
1-Wochen-Bereich:
$12.23
$14.85
52-Wochen-Spanne:
$12.23
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Firmenname
Oruka Therapeutics Inc
Sektor
Branche
Telefon
650-606-7910
Adresse
855 OAK GROVE AVE., MENLO PARK
Vergleichen Sie ORKA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
12.98 | 454.28M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-11 | Eingeleitet | Stifel | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-16 | Eingeleitet | TD Cowen | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-02-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Eingeleitet | Dawson James | Buy |
Alle ansehen
Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Buy” from Analysts - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year Low – Time to Sell? - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week LowWhat's Next? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 7.8%Should You Sell? - MarketBeat
Geode Capital Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year LowWhat's Next? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 8%What's Next? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) versus Myriad Genetics (NASDAQ:MYGN) Head to Head Comparison - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week LowShould You Sell? - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $43.17 Consensus Target Price from Analysts - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 3.2%Time to Sell? - MarketBeat
Critical Contrast: BG Medicine (OTCMKTS:BGMD) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Franklin Resources Inc. Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
H.C. Wainwright bullish on Oruka stock after early clinical success for ORKA-001 - Investing.com Canada
Oruka Therapeutics' (ORKA) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 - Yahoo Finance
Oruka Therapeutics enters exclusive licensing deal with Paragon - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) Shares Down 4.7%Should You Sell? - MarketBeat
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody - The Manila Times
Oruka Therapeutics Announces First Participants Dosed in - GlobeNewswire
Oruka Therapeutics Launches Phase 1 Trial of Revolutionary Long-Acting Psoriasis Treatment ORKA-001 - StockTitan
Wellington Management Group LLP Acquires New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Wellington Management Group LLP Takes $2.01 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Oruka Therapeutics to Join Prestigious Nasdaq Biotechnology Index in Major Milestone - StockTitan
Oruka Therapeutics (NASDAQ:ORKA) Sees Large Volume IncreaseShould You Buy? - MarketBeat
The Manufacturers Life Insurance Company Acquires New Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
The Manufacturers Life Insurance Company Invests $1.04 Million in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15% - Yahoo Finance
Frazier Life Sciences Management L.P. Purchases New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Janus Henderson Group PLC Acquires Shares of 236,116 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Point72 Asset Management L.P. Acquires Shares of 482,330 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
RTW Investments LP Takes $45.36 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Redmile Group LLC Acquires Shares of 411,728 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Fmr LLC Buys Shares of 4,682,300 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics: Strong Q3 and Strategic Advances - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Buy” by Brokerages - Defense World
Braidwell LP Acquires New Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Up 7.4%Here's Why - MarketBeat
Great Point Partners LLC Takes $12.61 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for ORKA - MarketBeat
Oruka stock stays Buy-rated as H.C. Wainwright emphasizes annual dosing potential for ORKA-001 - Investing.com UK
ARCA BIOPHARMA, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Oruka Therapeutics (NASDAQ:ORKA) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Fairmount Funds Management LLC's Strategic Acquisition in Oruka Therapeutics Inc - GuruFocus.com
Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference - The Manila Times
Oruka Therapeutics to Present at Piper Sandler Healthcare Conference | Psoriasis Drug Developer | ORKA Stock News - StockTitan
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference - GlobeNewswire
Oruka Therapeutics gains approval for preferred stock conversion - Investing.com
Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)
Es liegen keine Finanzdaten für Oruka Therapeutics Inc (ORKA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Oruka Therapeutics Inc-Aktie (ORKA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 24 '24 |
Buy |
3.20 |
189,856 |
606,873 |
2,081,168 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 25 '24 |
Buy |
3.05 |
30,227 |
92,292 |
2,111,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 03 '24 |
Buy |
3.55 |
166,042 |
589,565 |
1,648,577 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 11 '24 |
Buy |
3.45 |
94,537 |
326,304 |
1,891,312 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 10 '24 |
Buy |
3.46 |
55,463 |
192,130 |
1,796,775 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 08 '24 |
Buy |
3.46 |
47,492 |
164,190 |
1,724,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 05 '24 |
Buy |
3.43 |
28,326 |
97,065 |
1,676,903 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 09 '24 |
Buy |
3.43 |
16,917 |
58,091 |
1,741,312 |
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):